Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes
Background: In Papua, Indonesia, maternal malaria is prevalent, multidrug resistant and associated with adverse outcomes for mother and baby. In March 2006, anti-malarial policy was revised for the second and third trimester of pregnancy to dihydroartemisinin-piperaquine (DHP) for all species of mal...
Main Authors: | Poespoprodjo, J, Fobia, W, Kenangalem, E, Lampah, D, Sugiarto, P, Tjitra, E, Anstey, N, Price, R |
---|---|
Format: | Journal article |
Published: |
BioMed Central
2015
|
Similar Items
-
Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy
by: Poespoprodjo, JR, et al.
Published: (2014) -
Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy.
by: Jeanne Rini Poespoprodjo, et al.
Published: (2014-01-01) -
Treatment-seeking behavior after the implementation of a unified policy of dihydroartemisinin-piperaquine for the treatment of uncomplicated malaria in Papua, Indonesia
by: Devine, A, et al.
Published: (2017) -
Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemic.
by: Poespoprodjo, JR, et al.
Published: (2008) -
Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria.
by: Price, R, et al.
Published: (2007)